PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Open Access
Abstract
The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment.Keywords
This publication has 123 references indexed in Scilit:
- Long‐term p110α PI3K inactivation exerts a beneficial effect on metabolismEMBO Molecular Medicine, 2013
- T regulatory cells in B‐cell malignancy – tumour support or kiss of death?Immunology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center ReactionThe Journal of Immunology, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid StructuresJournal of Clinical Oncology, 2008
- Immune-mediated dormancy: an equilibrium with cancerJournal of Leukocyte Biology, 2008
- Cancer immunoediting from immune surveillance to immune escapeImmunology, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Inflammation and cancerNature, 2002